Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 880-885

  Charbonneau, Bridget ^a   Maurer, Matthew J ^a   Fredericksen, Zachary S ^a   Zent, Clive S ^a   Link, Brian K ^b   Novak, Anne J ^a   Ansell, Stephen M ^a   Weiner, George J ^b   Wang, Alice H ^a   Witzig, Thomas E ^a   Dogan, Ahmet ^a   Slager, Susan L ^a   Habermann, Thomas M ^a   Cerhan, James R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CFHR1 PROTEIN; CFHR5 PROTEIN; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; DOXORUBICIN; MEMBRANE COFACTOR PROTEIN; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHROMOSOME 1Q; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERMLINE VARIATION; HAZARD RATIO; HUMAN; HUMAN CELL; INNATE IMMUNITY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNITY, INNATE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84865367405     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23273     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011; 24: 203-216.
3. Hayashi D, Lee JC, Devenney-Cakir B, et al. Follicular non-Hodgkin's lymphoma. Clin Radiol 2010; 65: 408-420.
4. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-1208.
5. Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011; 86: 768-775.
6. Tilly H, Zelenetz A. Treatment of follicular lymphoma: current status. Leuk Lymphoma 2008; 49 Suppl 1: 7-17.
7. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39 Suppl C: 1-16.
8. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
9. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica 2010; 95: 135-143.
10. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
11. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006; 91: 176-183.
12. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-641.
13. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954-966.
14. Wang SY, Racila E, Taylor RP, et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008; 111: 1456-1463.
15. Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009; 114: 5322-5330.
16. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-1235.
17. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123.
18. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002; 87: 1119-1127.
19. Okroj M, Hsu YF, Ajona D, et al. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 2008; 45: 169-179.
20. Geis N, Zell S, Rutz R, et al. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 2010; 10: 922-931.
21. Terui Y, Sakurai T, Mishima Y, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006; 97: 72-79.
22. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14: 6697-6703.
23. Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009; 145: 614-623.
24. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010; 28: 412-417.
25. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007; 110: 4455-4463.
26. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: over 10, 000 targeted SNPs genotyped in a single tube assay. Genome Res 2005; 15: 269-275.
27. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
28. Boon CJ, van de Kar NC, Klevering BJ, et al. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol 2009; 46: 1573-1594.
29. Hogasen K, Jansen JH, Mollnes TE, et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054-1061.
30. Davila S, Wright VJ, Khor CC, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010; 42: 772-776.
31. McRae JL, Cowan PJ, Power DA, et al. Human factor H-related protein 5 (FHR-5). A new complement-associated protein. J Biol Chem 2001; 276: 6747-6754.
32. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9: 431-455.
33. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421: 388-392.
34. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-223.
35. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93: 193-200.
36. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957-2964.
37. Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115: 289-295.
38. Lingappa JR, Dumitrescu L, Zimmer SM, et al. Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease. PLoS One 2011; 6: e23413.
39. Durrant LG, Chapman MA, Buckley DJ, et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 2003; 52: 638-642.
40. Ikeda J, Morii E, Liu Y, et al. Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res 2008; 14: 4780-4786.
41. Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992; 149: 2055-2060.
42. Kawai T, Takeshita S, Imoto Y, et al. Associations between decay-accelerating factor polymorphisms and allergic respiratory diseases. Clin Exp Allergy 2009; 39: 1508-1514.
43. Kira R, Ihara K, Takada H, et al. Nonsense mutation in exon 4 of human complement C9 gene is the major cause of Japanese complement C9 deficiency. Hum Genet 1998; 102: 605-610.
44. Nagata M, Hara T, Aoki T, et al. Inherited deficiency of ninth component of complement: An increased risk of meningococcal meningitis. J Pediatr 1989; 114: 260-264.
45. Khajoee V, Ihara K, Kira R, et al. Founder effect of the C9 R95X mutation in Orientals. Hum Genet 2003; 112: 244-248.
46. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - A genomewide study. N Engl J Med 2007; 357: 1199-1209.